|
🐜
|
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
21 auth.
T. Barbui,
G. Barosi,
G. Birgegard,
F. Cervantes,
G. Finazzi,
M. Griesshammer,
C. Harrison,
H. Hasselbalch,
R. Hehlmann,
R. Hoffman,
...
J. Kiladjian,
N. Kröger,
R. Mesa,
M. McMullin,
A. Pardanani,
F. Passamonti,
A. Vannucchi,
A. Reiter,
R. Silver,
S. Verstovsek,
A. Tefferi
|
9 |
2011 |
9
🐜
|
|
🐜
|
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
27 auth.
J. Grinfeld,
J. Nangalia,
J. Baxter,
D. Wedge,
Nicos Angelopoulos,
R. Cantrill,
A. Godfrey,
E. Papaemmanuil,
G. Gundem,
C. Maclean,
J. Cook,
Laura O'Neil,
S. O’Meara,
J. Teague,
A. Butler,
...
C. Massie,
N. Williams,
Francesca L. Nice,
C. Andersen,
H. Hasselbalch,
P. Guglielmelli,
M. McMullin,
A. Vannucchi,
C. Harrison,
M. Gerstung,
A. Green,
P. Campbell
|
8 |
2018 |
8
🐜
|
|
🐜
|
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
23 auth.
T. Barbui,
A. Tefferi,
A. Vannucchi,
F. Passamonti,
R. Silver,
R. Hoffman,
S. Verstovsek,
R. Mesa,
J. Kiladjian,
R. Hehlmann,
...
A. Reiter,
F. Cervantes,
C. Harrison,
M. F. Mc Mullin,
H. Hasselbalch,
S. Koschmieder,
M. Marchetti,
A. Bacigalupo,
G. Finazzi,
N. Kroeger,
M. Griesshammer,
G. Birgegard,
G. Barosi
|
8 |
2018 |
8
🐜
|
|
🐜
|
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.
14 auth.
P. Beer,
P. Campbell,
L. Scott,
A. Bench,
W. Erber,
D. Bareford,
B. Wilkins,
J. Reilly,
H. Hasselbalch,
R. Bowman,
...
K. Wheatley,
G. Buck,
C. Harrison,
A. Green
|
8 |
2008 |
8
🐜
|
|
🦁
|
Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
H. Hasselbalch
|
8 |
2012 |
8
🦁
|
|
🐜
|
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.
13 auth.
G. Barosi,
G. Birgegard,
G. Finazzi,
M. Griesshammer,
C. Harrison,
H. Hasselbalch,
J. Kiladjian,
E. Lengfelder,
M. McMullin,
F. Passamonti,
...
J. Reilly,
A. Vannucchi,
T. Barbui
|
7 |
2009 |
7
🐜
|
|
🐜
|
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.
21 auth.
P. Campbell,
M. Griesshammer,
K. Döhner,
H. Döhner,
R. Kušec,
H. Hasselbalch,
T. Larsen,
N. Pallisgaard,
S. Giraudier,
M. Le Bousse-Kerdilès,
...
C. Desterke,
B. Guerton,
B. Dupriez,
D. Bordessoule,
P. Fenaux,
J. Kiladjian,
J. Viallard,
J. Briere,
C. Harrison,
A. Green,
J. Reilly
|
7 |
2006 |
7
🐜
|
|
🦁
|
Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
H. Hasselbalch
|
7 |
2013 |
7
🦁
|
|
🐜
|
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
18 auth.
H. Gisslinger,
C. Klade,
P. Georgiev,
D. Krochmalczyk,
L. Gercheva-Kyuchukova,
M. Egyed,
V. Rossiev,
P. Dulíček,
Á. Illés,
H. Pylypenko,
...
L. Sivcheva,
J. Mayer,
V. Yablokova,
K. Krejcy,
B. Grohmann-Izay,
H. Hasselbalch,
R. Kralovics,
J. Kiladjian
|
7 |
2020 |
7
🐜
|
|
🦁
|
MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives
H. Hasselbalch,
M. E. Bjørn
|
7 |
2015 |
7
🦁
|
|
🐜
|
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
14 auth.
G. Barosi,
G. Birgegard,
G. Finazzi,
M. Griesshammer,
C. Harrison,
H. Hasselbalch,
Jean‐Jacques Kiladijan,
E. Lengfelder,
R. Mesa,
M. F. Mc Mullin,
...
F. Passamonti,
J. Reilly,
A. Vannucchi,
T. Barbui
|
7 |
2010 |
7
🐜
|
